The HemOnc Pulse

Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Dr. Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.

Host Rahul Banerjee, MD, speaks with Drs. Frederik Schjesvold and Frida Askeland on myeloma trial results, relevance in the IMROZ/CEPHEUS era, and advances in treating elderly, frail patients.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

William Wierda, MD, PhD of the University of Texas MD Anderson discusses advances in chronic lymphocytic leukemia care, from targeted therapies and resistance to immune dysfunction and prevention with Blood Cancers Today Managing Editor, Nichole Tucker.

In this Editor’s Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.

A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.

Review of IMerge phase 3 data on imetelstat for lower-risk MDS and how prior therapies affect treatment outcomes, and other ASCO 2025 MDS updates with Andrew Brunner, MD.

During a session at The HemOnc Pulse Live! moderated by Naval Daver, MD, Eunice Wang, MD presents new insights in acute myeloid leukemia care, joined by Aditi Shastri, MBBS, Tapan Kadiya, MD, and Kelly Chien, MD for a rich panel on mutation loss, minimal residual disease, and transplant timing.

Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.